Avian Influenza Clade 2.3.4.4b: Global Impact and Summary Analysis of Vaccine Trials

Background: Avian influenza (AI), caused by orthomyxoviruses, is a globally significant disease affecting avian and non-avian species. It manifests in two variants, according to the two biovariants of the virus differentiated as highly pathogenic avian influenza (HPAI) and low pathogenic avian influ...

Full description

Saved in:
Bibliographic Details
Main Authors: László Kovács, Máté Farkas, Péter Ferenc Dobra, Georgia Lennon, László Péter Könyves, Miklós Rusvai
Format: Article
Language:English
Published: MDPI AG 2025-04-01
Series:Vaccines
Subjects:
Online Access:https://www.mdpi.com/2076-393X/13/5/453
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850256061549772800
author László Kovács
Máté Farkas
Péter Ferenc Dobra
Georgia Lennon
László Péter Könyves
Miklós Rusvai
author_facet László Kovács
Máté Farkas
Péter Ferenc Dobra
Georgia Lennon
László Péter Könyves
Miklós Rusvai
author_sort László Kovács
collection DOAJ
description Background: Avian influenza (AI), caused by orthomyxoviruses, is a globally significant disease affecting avian and non-avian species. It manifests in two variants, according to the two biovariants of the virus differentiated as highly pathogenic avian influenza (HPAI) and low pathogenic avian influenza (LPAI) strains, both of which compromise animal welfare, reduce productivity, and cause substantial economic loss. The zoonotic potential of HPAI strains, particularly the currently dominant clade 2.3.4.4b, raises concerns about public health and epidemic risks. This review assesses the results of current vaccine trials targeting HPAI clade 2.3.4.4b, emphasizing these studies because most outbreak strains in domestic poultry currently belong to this dominant clade. Methods: Multiple scientific databases comprised reports of research trials on vaccine efficacy against HPAI clade 2.3.4.4b. The Boolean term “Clade 2.3.4.4b AND vaccine” was entered into the following databases: PubMed, PubAg, Scopus, Cochrane Library, and ScienceDirect. Results: The resulting papers were analyzed. Studies revealed that antigenic similarity between vaccine and field strains enhances protective efficacy (PE), reduces viral shedding, and improves hemagglutination inhibition titers. While multivalent vaccines showed potential, results were inconsistent and varied depending on strain compatibility. Single-dose vaccines may provide sufficient PE for poultry, though ducks and geese often require multiple doses, and long-term PE is yet unknown. It was discovered that vector vaccines can provide appropriate PE against clade 2.3.4.4.b. Conclusions: Further analysis is needed as their effects may be short-lived, and subsequent doses may be required. Limited research exists on the long-term efficacy of these vaccines and their effectiveness in many avian species. Addressing these gaps is crucial for optimizing vaccination strategies. A re-evaluation of vaccination strategies is recommended but essential to implement adequate biosecurity measures on in poultry farms. This review synthesizes current evidence and may assist veterinarians and authorities in deciding whether to apply or license vaccines to reduce economic losses caused by AI.
format Article
id doaj-art-e86a114e3ae94b9684a0989f787423db
institution OA Journals
issn 2076-393X
language English
publishDate 2025-04-01
publisher MDPI AG
record_format Article
series Vaccines
spelling doaj-art-e86a114e3ae94b9684a0989f787423db2025-08-20T01:56:42ZengMDPI AGVaccines2076-393X2025-04-0113545310.3390/vaccines13050453Avian Influenza Clade 2.3.4.4b: Global Impact and Summary Analysis of Vaccine TrialsLászló Kovács0Máté Farkas1Péter Ferenc Dobra2Georgia Lennon3László Péter Könyves4Miklós Rusvai5Department of Animal Hygiene, Herd Health and Mobile Clinic, University of Veterinary Medicine, 1078 Budapest, HungaryPoultry-Care Kft., 5052 Újszász, HungaryDepartment of Pathology, University of Veterinary Medicine, 1078 Budapest, HungaryDepartment of Animal Hygiene, Herd Health and Mobile Clinic, University of Veterinary Medicine, 1078 Budapest, HungaryDepartment of Animal Hygiene, Herd Health and Mobile Clinic, University of Veterinary Medicine, 1078 Budapest, HungaryVet-Diagnostics Kft., 5000 Szolnok, HungaryBackground: Avian influenza (AI), caused by orthomyxoviruses, is a globally significant disease affecting avian and non-avian species. It manifests in two variants, according to the two biovariants of the virus differentiated as highly pathogenic avian influenza (HPAI) and low pathogenic avian influenza (LPAI) strains, both of which compromise animal welfare, reduce productivity, and cause substantial economic loss. The zoonotic potential of HPAI strains, particularly the currently dominant clade 2.3.4.4b, raises concerns about public health and epidemic risks. This review assesses the results of current vaccine trials targeting HPAI clade 2.3.4.4b, emphasizing these studies because most outbreak strains in domestic poultry currently belong to this dominant clade. Methods: Multiple scientific databases comprised reports of research trials on vaccine efficacy against HPAI clade 2.3.4.4b. The Boolean term “Clade 2.3.4.4b AND vaccine” was entered into the following databases: PubMed, PubAg, Scopus, Cochrane Library, and ScienceDirect. Results: The resulting papers were analyzed. Studies revealed that antigenic similarity between vaccine and field strains enhances protective efficacy (PE), reduces viral shedding, and improves hemagglutination inhibition titers. While multivalent vaccines showed potential, results were inconsistent and varied depending on strain compatibility. Single-dose vaccines may provide sufficient PE for poultry, though ducks and geese often require multiple doses, and long-term PE is yet unknown. It was discovered that vector vaccines can provide appropriate PE against clade 2.3.4.4.b. Conclusions: Further analysis is needed as their effects may be short-lived, and subsequent doses may be required. Limited research exists on the long-term efficacy of these vaccines and their effectiveness in many avian species. Addressing these gaps is crucial for optimizing vaccination strategies. A re-evaluation of vaccination strategies is recommended but essential to implement adequate biosecurity measures on in poultry farms. This review synthesizes current evidence and may assist veterinarians and authorities in deciding whether to apply or license vaccines to reduce economic losses caused by AI.https://www.mdpi.com/2076-393X/13/5/453highly pathogenic avian influenzaH5N1vaccinationOne Healthepidemicanimal welfare
spellingShingle László Kovács
Máté Farkas
Péter Ferenc Dobra
Georgia Lennon
László Péter Könyves
Miklós Rusvai
Avian Influenza Clade 2.3.4.4b: Global Impact and Summary Analysis of Vaccine Trials
Vaccines
highly pathogenic avian influenza
H5N1
vaccination
One Health
epidemic
animal welfare
title Avian Influenza Clade 2.3.4.4b: Global Impact and Summary Analysis of Vaccine Trials
title_full Avian Influenza Clade 2.3.4.4b: Global Impact and Summary Analysis of Vaccine Trials
title_fullStr Avian Influenza Clade 2.3.4.4b: Global Impact and Summary Analysis of Vaccine Trials
title_full_unstemmed Avian Influenza Clade 2.3.4.4b: Global Impact and Summary Analysis of Vaccine Trials
title_short Avian Influenza Clade 2.3.4.4b: Global Impact and Summary Analysis of Vaccine Trials
title_sort avian influenza clade 2 3 4 4b global impact and summary analysis of vaccine trials
topic highly pathogenic avian influenza
H5N1
vaccination
One Health
epidemic
animal welfare
url https://www.mdpi.com/2076-393X/13/5/453
work_keys_str_mv AT laszlokovacs avianinfluenzaclade2344bglobalimpactandsummaryanalysisofvaccinetrials
AT matefarkas avianinfluenzaclade2344bglobalimpactandsummaryanalysisofvaccinetrials
AT peterferencdobra avianinfluenzaclade2344bglobalimpactandsummaryanalysisofvaccinetrials
AT georgialennon avianinfluenzaclade2344bglobalimpactandsummaryanalysisofvaccinetrials
AT laszlopeterkonyves avianinfluenzaclade2344bglobalimpactandsummaryanalysisofvaccinetrials
AT miklosrusvai avianinfluenzaclade2344bglobalimpactandsummaryanalysisofvaccinetrials